Hi,
Great news for the immunocompromised community including us. Invivyd announced late last week the emergency use authorization of their new pre-exposure prophylaxis (PrEP) for COVID-19, PEMGARDA™ (VYD222).
It’s a one-hour infusion and lasts 3 months and based on titers should be effective against the present VOC of SARS-CoV2. And it was studied in the immunocompromised! It does have a 0.6% risk of anaphylaxis so discuss with your healthcare team but this is great news overall for CLL patients.
Here is the link to the press release: investors.invivyd.com/news-...
Here is the link to the patient fact sheet: invivyd.com/wp-content/uplo...
This makes me happy because as we know for CLL/SLL patients protection from vaccines is incomplete and now we have another prevention option similar to EVUSHELD when it was effective.
CLL Society will be posting more information on our website very soon.
Stay strong.
We are all in this together.
Brian
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc